GSK Profit Beats Estimates on HIV, Cancer Medicines
GSK Plc’s profit was higher than analysts expected in the first quarter, helped by the drugmaker’s specialty medicines for HIV, cancer and immune diseases.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.